| Acquired by | Illumina |
| Date | 1/13 |
| Website | verinata.com |
| Category | BioTech |
| Phone | (650) 632-1680 |
| info@verinata.com | |
| Employees |
| TOTAL | $48.5M |
| FUNDING TOTAL | $48.5M |
| Series C, 8/11 Mohr Davidow Ventures Sutter Hill Ventures Alloy Ventures | $48.5M |
Verinata is driven by a sole, extraordinary purpose – maternal and fetal health. Our initial focus is to develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities using our proprietary technologies. We aim to reduce the anxiety associated with today’s multi-step process, the unacceptable false-positive rates, the non-specific and sometimes confusing results of current prenatal screening methods, as well as the risk of current invasive procedures. In support of national guidelines recommending first trimester aneuploidy risk assessment, we believe women who desire such an assessment should be offered a single blood draw test with a definitive result. Verinata is conducting a prospective, blinded pivotal study to clinically validate the sensitivity and specificity of its first prenatal test on a large scale with results of the study expected in 2011.
